IKT

Insider Trades

Name	Value	Action	Price	Current Price
Sands Capital Life Sciences Pulse Fund II, L.P.10 Percent Owner $3.0M2.1M shares BuyNov 21, 2025 $1.45 --

News

globenewswire.comInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activityglobenewswire.comMay 12

globenewswire.comInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertensionglobenewswire.comApr 7

globenewswire.comInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comApr 3

globenewswire.comInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activityglobenewswire.comMar 26

Trade IKT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a pharmaceutical firm in the clinical development stage, concentrating its efforts on pioneering treatments for Parkinson's Disease (PD) and a range of associated neurological conditions that impact both the brain and other parts of the body. The company's investigational pipeline includes IkT-148009, a small molecule designed to inhibit Abelson tyrosine kinase. This candidate aims to address not only Parkinson's disease itself but also early-stage gastrointestinal complications often experienced by PD patients, such as swallowing difficulties (dysphagia), neurologically-induced constipation, and multiple system atrophy. Additionally, Inhibikase is advancing IkT-001Pro through preclinical development. This prodrug, derived from the anti-cancer agent Imatinib, is intended to lessen typical gastrointestinal side effects while providing treatment for blood and stomach cancers. Beyond these primary compounds, the company is also pursuing various research programs focused on other neurological disorders. Inhibikase actively collaborates on research and development initiatives with several prominent academic institutions, including The Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. Established in 2008, Inhibikase Therapeutics, Inc. maintains its corporate headquarters in Atlanta, Georgia.

CEO: Mark T. Iwicki
IPO Date: Dec 23, 2020

Market Data

Open: $1.72
High: $1.83
Low: $1.71
Volume: 1.4M
Avg Volume: 1M
52W High: $2.26
52W Low: $1.33

Valuation

Market Cap: $242M
Enterprise Value: $192M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-28M
Revenue: $0
Net Income: $-48M
Cash: $139M
Debt: $0

Events

EarningsAug 13

EPS est. -0.09